PDF Cover

Nabilone Market

The market for Nabilone was estimated at $132 million in 2024; it is anticipated to increase to $204 million by 2030, with projections indicating growth to around $293 million by 2035.

Report ID:DS1802370
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Nabilone
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Nabilone Market Outlook

Revenue, 2024

$132M

Forecast, 2034

$272M

CAGR, 2025 - 2034

7.5%

The Nabilone industry revenue is expected to be around $142.2 million in 2025 and expected to showcase growth with 7.5% CAGR between 2025 and 2034. Building on this growth trajectory, the Nabilone market continues to gain importance within the pharmaceutical landscape due to the increasing focus on effective symptom management for patients experiencing severe nausea, vomiting, and treatment-related discomfort. Growing awareness among healthcare professionals regarding cannabinoid-based therapeutics, coupled with advancements in supportive cancer care, is strengthening the adoption of Nabilone across multiple healthcare settings. The market is also benefiting from ongoing clinical research exploring broader therapeutic applications, favorable regulatory developments in selected regions, and rising demand for personalized treatment approaches. Furthermore, the increasing burden of chronic diseases and the need for improved patient quality of life continue to reinforce the relevance of Nabilone in modern therapeutic protocols.

Nabilone is a synthetic cannabinoid that mimics the effects of naturally occurring cannabinoids and is primarily used to manage chemotherapy-induced nausea and vomiting in patients who do not respond adequately to conventional antiemetic therapies. The drug is recognized for its ability to interact with cannabinoid receptors, helping regulate symptoms associated with treatment-related distress. Beyond its established oncology applications, research is examining its potential role in pain management, neurological disorders, appetite stimulation, and palliative care. Recent market trends indicate growing interest in cannabinoid-based medicines, increased investment in specialized pharmaceutical research, and expanding clinical investigations into novel therapeutic uses. From an AI-driven healthcare perspective, advanced analytics and real-world evidence platforms are supporting patient stratification, treatment optimization, and outcome monitoring, enabling more targeted utilization of Nabilone while improving clinical decision-making and patient-centric care strategies.

Nabilone market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Nabilone Market Outlook

Market Key Insights

  • The Nabilone market is projected to grow from $132.3 million in 2024 to $273 million in 2034. This represents a CAGR of 7.5%, reflecting rising demand across Chemotherapy-Induced Nausea and Vomiting, Neuropathic pain, and Central pain syndrome.

  • Valeant Pharmaceuticals International Inc, Meda Pharmaceuticals, Bausch Health Companies Inc are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Canada are the top markets within the Nabilone market and are expected to observe the growth CAGR of 4.9% to 7.2% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.6% to 10.3%.

  • Transition like A Shift towards Personalized Medication is expected to add $7 million to the Nabilone market growth by 2030.

  • The Nabilone market is set to add $140 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    increasing demand for synthetic cannabinoids, and

    Advancements in Research and Development, Nabilone market to expand 106% between 2024 and 2034.

nabilone market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Nabilone - Country Share Analysis

Opportunities in the Nabilone

Rising cancer incidence and improving access to oncology care in Asia-Pacific countries are creating significant opportunities for Nabilone-based therapies. Healthcare providers are increasingly seeking effective alternatives for patients who experience inadequate relief from conventional antiemetics. Strategic collaborations between pharmaceutical companies and regional healthcare networks are supporting broader product availability and physician awareness. AI-driven patient outcome monitoring is also further helping identify suitable candidates for cannabinoid-based treatments. The oral Nabilone segment used for chemotherapy-induced nausea and vomiting management is expected to witness the strongest growth, particularly across emerging Asian healthcare markets.

Growth Opportunities in North America and Europe

North America, particularly the USA, has a dominant place in the Nabilone market owing to the wide acceptance and implementation of cannabinoid therapeutic alternatives. This regions demand for Nabilone is significantly driven by an increasing number of therapeutic applications in fields like oncology and neurology. The noteworthy competitors in this region include leading pharmaceutical companies that have invested heavily in research and development activities for Nabilone and related products. The increasing awareness and openness towards the benefits of Nabilone in pain management and appetite stimulation offer high potential for market expansion in North America. The overall market growth in this region is also driven by supportive regulations and increasing healthcare expenditures.
Europe, with a particular focus on the UK and Germany, holds a significant share in the global Nabilone market. The regions demand pattern showcases an upwards trajectory, largely fueled by an aging population facing chronic diseases and advances in cannabinoid research. Key players in this arena range from pharmaceutical giants to emerging biotech firms with a focus on cannabinoid application. The increasing off-label usage of Nabilone as an adjunct treatment in neuropathic pain and fibromyalgia symbolizes untapped opportunities in these countries. The ever-evolving legal framework surrounding the medical use of cannabinoids is another important driver promoting market growth in Europe.

Market Dynamics and Supply Chain

01

Driver: Rising Oncology Supportive Care Demand and Expanded Cannabinoid Based Therapeutic Acceptance

The nabilone market is also strongly driven by rising demand for supportive oncology care and broader acceptance of cannabinoid based medicines. Growth in cancer incidence has also increased the use of advanced chemotherapy regimens, creating a sustained need for effective treatments for chemotherapy induced nausea and vomiting. Nabilone is also increasingly prescribed when standard antiemetics fail, positioning it as a valuable niche therapy. In parallel, regulatory and clinical acceptance of cannabinoid based therapeutics has also expanded, supported by improved clinical evidence and clearer prescribing guidelines. Hospitals and specialty clinics are also becoming more comfortable integrating synthetic cannabinoids into pain and symptom management protocols. This dual trend supports steady prescription growth, wider physician adoption, and increased reimbursement discussions. Together, oncology driven demand and evolving cannabinoid acceptance are also enabling manufacturers to invest in formulation refinement, targeted marketing, and expanded distribution across regulated pharmaceutical channels. This momentum enhances long term revenue visibility and strengthens competitive positioning globally overall.
Advancements in synthetic cannabinoid formulations represent a key driver shaping nabilone market growth. Manufacturers are also focusing on improved purity, dose consistency, and controlled release profiles to enhance safety and therapeutic reliability. These formulation improvements reduce variability in patient response and support more predictable clinical outcomes. Enhanced manufacturing controls also help address historical concerns related to cannabinoid tolerability and side effects. As a result, physicians show greater confidence when prescribing nabilone for chronic pain and neurological indications. Technological progress in pharmaceutical synthesis further supports regulatory compliance and quality assurance across markets. This driver strengthens nabilone’s positioning as a clinically dependable option, supporting expanded use beyond niche indications and encouraging long term adoption within regulated healthcare systems. This trend aligns with demand for safer alternatives to opioids in pain management globally today.
02

Restraint: Stringent regulatory restrictions and limited approval pathways constrain nabilone market expansion

Nabilone faces tight regulatory scrutiny in many regions due to its classification as a synthetic cannabinoid, which limits approval and prescription flexibility. In jurisdictions with strict controlled substance laws, physicians encounter additional administrative requirements for prescribing nabilone, lowering its adoption compared with standard antiemetics or analgesics. For example, regulators in several Asian and Middle Eastern markets have delayed or restricted cannabinoid based drug approvals, slowing market entry and demand. These regulatory barriers restrict revenue growth potential and lead manufacturers to focus only on markets with established cannabinoid frameworks, reducing global scale and delaying broader commercial uptake.
03

Opportunity: Growing Palliative Care Demand Among Aging Chronic Disease Patients and Advancing Neurological Disorder Research Through Precision Medicine Programs

The expanding elderly population and increasing prevalence of chronic illnesses are driving demand for symptom-management therapies within palliative and supportive care settings. Nabilone is gaining attention for its potential to improve patient comfort by addressing treatment-related nausea, appetite loss, and associated distress. Healthcare institutions are integrating data analytics and personalized care models to optimize symptom-control strategies. As patient-centered care becomes a priority, opportunities are emerging in long-term care and hospice environments. The palliative care application segment is expected to grow the most, particularly in North America and Western Europe.
Ongoing clinical investigations into neurological and pain-related conditions are opening new avenues for Nabilone adoption beyond traditional oncology applications. Research organizations are leveraging AI-assisted clinical trial design and real-world evidence platforms to evaluate therapeutic effectiveness across targeted patient groups. Pharmaceutical companies are forming strategic partnerships with academic institutions to accelerate innovation and regulatory progress. Growing interest in personalized medicine is supporting exploration of cannabinoid-based therapies for complex neurological symptoms. Among emerging opportunities, neurological disorder applications are expected to register the highest long-term growth potential, especially in developed healthcare markets.
04

Challenge: Competition from alternative therapies and perceptions around efficacy limit nabilone use in practice

The presence of alternative antiemetic and pain management options restrains nabilone demand. Agents such as ondansetron for chemotherapy induced nausea and advanced neuropathic pain drugs like gabapentinoids are well established, often with stronger clinical guideline support. Prescribers may prefer these alternatives due to familiarity, perceived efficacy, or fewer stigma related concerns around cannabinoid use. For instance, many oncologists choose multi drug antiemetic regimens over nabilone, affecting prescription volume and market revenue. This competitive pressure reduces nabilone’s share in key therapeutic segments and challenges manufacturers to demonstrate clear differentiation to clinicians.

Supply Chain Landscape

1

Raw Material Procurement

Sigma AldrichCayman Chemical Company
2

Drug Formulation & Development

Tocris BioscienceSanta Cruz Biotechnology
3

Regulatory Compliance & Approval

United States FDAEuropean Medicines Agency
4

Distribution & End User

Pharmaceutical CompaniesMedical Research Facilities
Nabilone - Supply Chain

Use Cases of Nabilone in Chemotherapy-Induced Nausea & Vomiting

Chemotherapy-Induced Nausea and Vomiting : Nabilone is primarily used in chemotherapy induced nausea and vomiting as an oral synthetic cannabinoid for oncology patients who do not respond adequately to conventional antiemetics. Oral capsule formulations are most commonly prescribed in this application due to precise dosing and ease of administration during chemotherapy cycles. Nabilone acts on central cannabinoid receptors to reduce nausea signals and suppress vomiting reflexes. Its unique advantage lies in effectiveness for refractory CINV cases, especially when serotonin antagonists or corticosteroids show limited results. This application supports improved treatment adherence and quality of life for cancer patients undergoing aggressive chemotherapy regimens.
Neuropathic pain : In neuropathic pain management, nabilone is used as an oral therapeutic option for patients with chronic nerve related pain conditions. Standard oral nabilone capsules are commonly prescribed by pain specialists for patients who do not achieve adequate relief from antidepressants or anticonvulsants. Nabilone modulates pain perception by interacting with cannabinoid receptors in the central nervous system, helping reduce pain intensity and discomfort. Its advantage lies in addressing complex pain pathways rather than only inflammatory responses. This makes it suitable for long term neuropathic pain conditions such as diabetic neuropathy, post surgical nerve pain, and multiple sclerosis related nerve pain.
Central pain syndrome : Nabilone is increasingly utilized in central pain syndrome where pain originates from damage to the brain or spinal cord. Oral nabilone formulations are mainly used in neurological care settings to manage persistent pain symptoms that are difficult to treat with traditional analgesics. By acting on central cannabinoid receptors, nabilone helps regulate abnormal pain signaling within the central nervous system. Its ability to target central pain mechanisms offers a distinct advantage in conditions such as spinal cord injury or stroke related pain. This application supports improved symptom control and functional comfort for patients with complex neurological pain disorders.

Impact of Industry Transitions on the Nabilone Market

As a core segment of the Pharmaceutical industry, the Nabilone market develops in line with broader industry shifts. Over recent years, transitions such as A Shift towards Personalized Medication and Increased Adoption of Telemedicine have redefined priorities across the Pharmaceutical sector, influencing how the Nabilone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

A Shift towards Personalized Medication

The pharmaceutical industry has been progressively embracing personalized medication, focusing on the individuals specific condition and health profile. The role of Nabilone, an effective prescription drug used for managing severe nausea and vomiting linked with chemotherapy, stands to be amplified. As health care professionals seek to optimize treatment plans for patients, pharmacogenomics is growing in importance, with medicines like Nabilone at the core. This amplifies the potential for Nabilone to tailor treatment to individual patient needs, minimizing adverse reactions and increasing improved treatment outcomes.
02

Increased Adoption of Telemedicine

The increased adoption of telemedicine is reshaping how nabilone reaches patients and prescribers. Virtual oncology and pain management consultations now allow eligible patients to discuss treatment options, manage side effects, and receive prescriptions for nabilone without frequent hospital visits. This transition is particularly impactful for chemotherapy induced nausea and chronic neuropathic pain patients who often require ongoing symptom control. Telehealth platforms integrated with e prescribing systems are also improving treatment continuity and adherence. Associated industries such as digital pharmacies and remote patient monitoring services are benefiting, as demand grows for home delivery and follow up care solutions. Overall, telemedicine is expanding market access for nabilone while supporting more efficient healthcare delivery models.